focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Issue of Shares

18 Dec 2012 07:00

RNS Number : 7366T
Phorm Corporation Limited
18 December 2012
 

18 December 2012

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE

UNITED STATES, CANADA, JAPAN OR AUSTRALIA

 

Phorm Corporation Limited ("Phorm" or the "Company")

 

ISSUE OF SHARES

 

Phorm (AIM: PHRM), the internet personalisation technology company, wishes to notify that, further to the announcement regarding the completion of the Company's re-domicile on 11 September 2012, the Company has received from a shareholder with a US registered address an Investor Questionnaire confirming that it is entitled to the Share Consideration.

 

Accordingly, 14,680 shares have been allotted and will be admitted to trading on 21December 2012 ("Admission"). The number of ordinary shares in issue at Admission for notification of interests in the share capital of the Company will be 90,999,361. This number may increase up to 91,046,515 subject to shareholders with US registered addresses holding in aggregate 47,154 Phorm Shares on Admission returning their Investor Questionnaires within 6 months from the date of completion of the re-domicile confirming that they are entitled to the Share Consideration. Any admission of new ordinary shares will be notified by the Company.

 

Capitalised terms in this announcement have the meaning given to it in the Circular in relation to the Company's re-domiciliation which can be found on the Company's website at www.phorm.com.

 

 

For Enquiries

Phorm Corporation Limited

Mark Williams (analysts & investors) +44 20 7297 2326

Alex Laity (media) +44 20 7297 2710

 

Liberum Capital +44 20 3100 2222

(Nominated Advisor and Joint Broker)

Chris Bowman

Richard Bootle

 

Mirabaud Securities LLP +44 20 7321 2508

(Joint Broker)

Jason Woollard

Peter Krens

Hudson Sandler +44 20 7796 4133

Charlie Jack

Charlie Barker

 

- ends -

 

 

About Phorm

 

Phorm is a global personalisation technology company that makes content and advertising more relevant to the consumer. Phorm's innovative platform preserves user privacy and delivers a more interesting online experience.

 

Phorm's partners include leading Internet Service Providers (ISPs), Publishers, Ad Networks and Advertisers.

Phorm, under a predecessor holding company, was admitted to the AIM market of the London Stock Exchange in 2004 and has over 140 employees and contractors.

For more information, please visit: www.phorm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBKODKOBDDQBD

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.